Clinical trial NCT01429909: Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease
Official title: Optimization of fMRI for the Study of Basal Ganglia Activation in Parkinson's Disease: T2* Measurement in the Cortex and the Basal Ganglia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson's Disease
Keywords: Functional magnetic resonance imaging
T2*
cortex and basal ganglia
Parkinson's disease
Lead sponsor: University Hospital, Clermont-Ferrand
Sponsor class: OTHER
First posted: 2011-09-07
Enrollment: 19
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Functional magnetic resonance imaging (fMRI) is a non-invasive imaging technique assessing neuronal activations during motor or cognitive tasks. The MRI sequences used are currently optimized for the study of cortex activations, particularly concerning the echo time (TE).Very few studies are interested in optimizing the fMRI for the study of the basal ganglia, structure implicated in many neurological diseases such as Parkinson's disease. The T2 \* is a tissue parameter dependent of iron content, which differs with brain structures and probably also with age and in case of neurodegenerative disease. Optimal TE s should correspond to the T2 \* of studied brain structure The primary purpose is to optimize the fMRI by a quantitative measurement of the T2\* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2\*.

Detailed description: 80 subjects (40 PD patients and 40 paired healthy volunteers (on sex and age)) aged 40-80 years will be included. PD patients will be recruited in the Department of Neurology of CHU of Clermont-Ferrand. Healthy volunteers will be selected in clinical trial database. This study will consist of one visit (at J0) during which subjects will undergo a MRI (a single acquisition of 40 minutes approximately). PD patients will be further questioned on their disease and will benefit from a neurological examination

Eligibility criteria: Inclusion Criteria:

* For patients :
* Patients with idiopathic Parkinson's disease according to UKPDSBB criterias
* Men or women aged between 40 to 80 years
* not treated with deep brain stimulation

For healthy subjects

- Men or women aged between 40 to 80 years

Exclusion Criteria:

For patients

* Dementia (MMS\<24)
* Contraindication to MRI.
* Under guardianship
* In excluding period for another study

For healthy subjects

* Antecedent of neurodegenerative diseases or psychiatric diseases
* Contraindication to MRI
* Under guardianship
* In excluding period for another study

Primary outcomes:
measure: The quantitative measurement of T2* in the cortex and basal ganglia using MRI, made à J0.
timeFrame: at day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Clermont-Ferrand
country: France
facility: Chu Clermont-Ferrand
Study officials:
affiliation: University Hospital, Clermont-Ferrand
name: Miguel ULLA
role: PRINCIPAL_INVESTIGATOR
References: